Clinical Trial Results: Positive or negative results from clinical trials for MacroGenics' cancer therapies significantly impact investor confidence and stock price.

Regulatory Approval: FDA approval or rejection of MacroGenics' drug candidates is a major catalyst for stock price movement.

Competition: The presence and success of competing cancer therapies influence the market share and potential revenue of MacroGenics' products.

Partnerships/Collaborations: Strategic partnerships with other pharmaceutical companies can boost investor confidence and provide financial resources.

Financial Performance: Revenue, expenses, and profitability reports can affect investor perception of MacroGenics' financial health and future prospects.

Market Sentiment: Overall market conditions, investor risk appetite, and broader trends in the biotechnology sector impact MGTX's stock.

Drug Sales: Actual sales figures for approved MacroGenics drugs directly impact the company's revenue and influence stock valuation.

Management Team: The expertise and leadership of the management team influence investor confidence in the company's strategic direction.

Intellectual Property: Strong patent protection for MacroGenics' drug candidates is crucial for maintaining market exclusivity and attracting investment.